{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:57:25Z","timestamp":1781063845307,"version":"3.54.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kroner-Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004038","name":"Jung Foundation for Science and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.trecan.2026.01.008","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:52:55Z","timestamp":1773147175000},"page":"481-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The rationale for targeting nectin-4 in pancreatic cancer"],"prefix":"10.1016","volume":"12","author":[{"given":"Sarah","family":"Cronjaeger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5329-3164","authenticated-orcid":false,"given":"Adrian M.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.01.008_bb0005","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.01.008_bb0010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41571-025-01077-z","article-title":"The tumour microenvironment in pancreatic cancer \u2013 new clinical challenges, but more opportunities","volume":"22","author":"Kung","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.01.008_bb0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.01.008_bb0020","article-title":"Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer","volume":"11","author":"Heiduk","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.trecan.2026.01.008_bb0025","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1158\/1078-0432.CCR-23-0258","article-title":"TIGIT expression delineates T-cell populations with distinct functional and prognostic impact in pancreatic cancer","volume":"29","author":"Heiduk","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.01.008_bb0030","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.01.008_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2021.106865","article-title":"Nectin-4 promotes lymphangiogenesis and lymphatic metastasis in breast cancer by regulating CXCR4-LYVE-1 axis","volume":"140","author":"Sethy","year":"2021","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.trecan.2026.01.008_bb0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13402-018-0417-1","article-title":"Nanoquinacrine sensitizes 5-FU-resistant cervical cancer stem-like cells by down-regulating Nectin-4 via ADAM-17 mediated NOTCH deregulation","volume":"42","author":"Nayak","year":"2019","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.trecan.2026.01.008_bb0045","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.trecan.2026.01.008_bb0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin\u2013driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.trecan.2026.01.008_bb0055","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.01.008_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS719","article-title":"A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC)","volume":"42","author":"Kasi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.01.008_bb0065","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2767-9764.CRC-24-0176","article-title":"ETx-22, a novel nectin-4\u2013directed antibody\u2013drug conjugate, demonstrates safety and potent antitumor activity in low-nectin-4\u2013expressing tumors","volume":"4","author":"Lopez","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.trecan.2026.01.008_bb0070","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1200\/JCO.23.01107","article-title":"Results from first-in-human phase I dose-escalation study of a novel bicycle toxin conjugate targeting EphA2 (BT5528) in patients with advanced solid tumors","volume":"42","author":"Bashir","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580332600021X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240580332600021X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:00:12Z","timestamp":1781060412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240580332600021X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S240580332600021X"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.01.008","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The rationale for targeting nectin-4 in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}